Invasive and Severe Localized Infections Caused by Fusarium Species and Other Rare Filamentous Fungi in Greece: A Prospective Epidemiological Study
Journal of Fungi · 04.11.2026 · 12 (11) · 829
DOI: 10.3390/jof12110829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 04.11.2026. Verfasst von Maria Drogari-Apiranthitou und 27 weiteren Autor:innen. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Hellas L.EPE.
Abstract (Originalsprache)
Infections caused by filamentous fungi other than Aspergillus spp. or Mucorales are uncommon but often severe, particularly in immunocompromised individuals. We conducted a prospective, nationwide, multicenter study to investigate the epidemiology, clinical spectrum, antifungal susceptibility, treatment, and outcomes of invasive and severe localized rare mold infections in Greece from 2009 to 2025. We documented 118 cases, with no significant temporal trend. The most frequent underlying conditions were hematologic malignancy (27.1%), hematopoietic cell transplantation/graft-versus-host disease (11.9%), trauma or other skin conditions (13.6%), pulmonary disease or respiratory failure (5.9%), and ocular predisposing factors for keratitis (22.9%). Bloodstream and corneal infections predominated. Fusarium spp. accounted for 66.9% of cases, followed by Scedosporium apiospermum (9.3%). Six breakthrough infections occurred during mold-active prophylaxis or empirical treatment, all caused by Fusarium spp. Amphotericin B showed the greatest in vitro activity against Fusarium spp., whereas voriconazole was most active against non-Fusarium molds. Clinical outcomes did not consistently correspond with in vitro antifungal activity. Crude mortality among non-ocular infections was 44.4% and was significantly higher in patients with hematologic malignancy or hematopoietic cell transplantation than in other patients (65% vs. 28%; p = 0.018). The number of reported rare mold infections in Greece showed no increasing trend, but they were associated with substantial morbidity and high mortality, particularly among severely immunocompromised patients.
Förderung
- Gilead Sciences Hellas L.EPE
Zitieren
APA
Drogari-Apiranthitou, M., Siopi, M., Vyzantiadis, T., Sidiropoulou, A., Mpakosi, A., Vrioni, G., Argyropoulou, A., Orfanidou, M., Mamali, V., Roilides, E., Kourti, M., Petrikkos, L., Stamouli, M., Christofidou, M., Spiliopoulou, A., Balaska, A., Papathanasiou, M., Daskalaki, M., Pirounaki, M., …, & Petrikkos, G. (2026). Invasive and Severe Localized Infections Caused by Fusarium Species and Other Rare Filamentous Fungi in Greece: A Prospective Epidemiological Study. Journal of Fungi, 12(11), 829. https://doi.org/10.3390/jof12110829
Vancouver
Drogari-Apiranthitou M, Siopi M, Vyzantiadis T, Sidiropoulou A, Mpakosi A, Vrioni G, et al. Invasive and Severe Localized Infections Caused by Fusarium Species and Other Rare Filamentous Fungi in Greece: A Prospective Epidemiological Study. Journal of Fungi. 2026;12(11):829. doi:10.3390/jof12110829
BibTeX
@article{DrogariApiranthitou2026,
author = {Drogari-Apiranthitou, Maria and Siopi, Maria and Vyzantiadis, Timoleon-Achilleas and Sidiropoulou, Anna and Mpakosi, Alexandra and Vrioni, Georgia and Argyropoulou, Athina and Orfanidou, Maria and Mamali, Vassiliki and Roilides, Emmanuel and Kourti, Maria and Petrikkos, Loizos and Stamouli, Maria and Christofidou, Myrto and Spiliopoulou, Anastasia and Balaska, Asimina and Papathanasiou, Maria and Daskalaki, Maria and Pirounaki, Maria and Charalampaki, Nicoletta and Pavleas, Ioannis and Skiada, Anna and Tofas, Polydoros and Mastrogiannaki-Marini, Alexandra and Meletiadis, Joseph and Panayiotides, Ioannis and Tsiodras, Sotirios and Petrikkos, George},
title = {Invasive and Severe Localized Infections Caused by Fusarium Species and Other Rare Filamentous Fungi in Greece: A Prospective Epidemiological Study},
journal = {Journal of Fungi},
year = {2026},
volume = {12},
number = {11},
pages = {829},
doi = {10.3390/jof12110829}
}
EUVIMED